se ha leído el artículo
array:24 [ "pii" => "S1699258X16300432" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2016.04.013" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "927" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2017;13:197-200" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2519 "formatos" => array:3 [ "EPUB" => 160 "HTML" => 1542 "PDF" => 817 ] ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S2173574317300850" "issn" => "21735743" "doi" => "10.1016/j.reumae.2016.04.016" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "927" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2017;13:197-200" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 380 "formatos" => array:3 [ "EPUB" => 42 "HTML" => 219 "PDF" => 119 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Association between serum dickkopf-1 levels and disease duration in axial spondyloarthritis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "197" "paginaFinal" => "200" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Asociación entre niveles séricos de Dickkopf-1 y duración de la enfermedad en espondiloartritis axial" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Roxana Rubio Vargas, Enrique Melguizo Madrid, Concepción González Rodríguez, Federico Navarro Sarabia, Carmen Dominguez Quesada, Rafael Ariza Ariza, Victoria Navarro Compán" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Roxana" "apellidos" => "Rubio Vargas" ] 1 => array:2 [ "nombre" => "Enrique" "apellidos" => "Melguizo Madrid" ] 2 => array:2 [ "nombre" => "Concepción" "apellidos" => "González Rodríguez" ] 3 => array:2 [ "nombre" => "Federico" "apellidos" => "Navarro Sarabia" ] 4 => array:2 [ "nombre" => "Carmen" "apellidos" => "Dominguez Quesada" ] 5 => array:2 [ "nombre" => "Rafael" "apellidos" => "Ariza Ariza" ] 6 => array:2 [ "nombre" => "Victoria" "apellidos" => "Navarro Compán" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1699258X16300432" "doi" => "10.1016/j.reuma.2016.04.013" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X16300432?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317300850?idApp=UINPBA00004M" "url" => "/21735743/0000001300000004/v1_201707050008/S2173574317300850/v1_201707050008/en/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1699258X16300407" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2016.04.010" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "924" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2017;13:201-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4007 "formatos" => array:3 [ "EPUB" => 166 "HTML" => 2592 "PDF" => 1249 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "201" "paginaFinal" => "209" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tofacitinib, un inhibidor oral de la quinasa Janus, para el tratamiento de artritis reumatoide en pacientes de Latinoamérica: eficacia y seguridad de estudios fase 3 y de extensión a largo plazo" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2877 "Ancho" => 3410 "Tamanyo" => 505146 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">LTE study efficacy for normal approximation to A) ACR20, B) ACR50, C) ACR70 response rates (SE), D) mean DAS28-4(ESR) scores, and E) mean change from baseline in HAQ-DI per visit. Full analysis set, no imputation. Dashed line in Panel E represents MCID (reduction in HAQ-DI score ≥0.22). American College of Rheumatology (ACR), twice daily (BID), disease activity score (28 joints) (DAS28), erythrocyte sedimentation rate (ESR), health assessment questionnaire-disability index (HAQ-DI), long-term extension (LTE), minimum clinically important difference (MCID), standard error (SE).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Sebastião Cezar Radominski, Mario Humberto Cardiel, Gustavo Citera, Annelise Goecke, Juan Jose Jaller, Andrea Barranjard Vannucci Lomonte, Pedro Miranda, Patricia Velez, Daniel Xibillé, Kenneth Kwok, Ricardo Rojo, Erika Gabriela García" "autores" => array:12 [ 0 => array:2 [ "nombre" => "Sebastião Cezar" "apellidos" => "Radominski" ] 1 => array:2 [ "nombre" => "Mario Humberto" "apellidos" => "Cardiel" ] 2 => array:2 [ "nombre" => "Gustavo" "apellidos" => "Citera" ] 3 => array:2 [ "nombre" => "Annelise" "apellidos" => "Goecke" ] 4 => array:2 [ "nombre" => "Juan Jose" "apellidos" => "Jaller" ] 5 => array:2 [ "nombre" => "Andrea Barranjard Vannucci" "apellidos" => "Lomonte" ] 6 => array:2 [ "nombre" => "Pedro" "apellidos" => "Miranda" ] 7 => array:2 [ "nombre" => "Patricia" "apellidos" => "Velez" ] 8 => array:2 [ "nombre" => "Daniel" "apellidos" => "Xibillé" ] 9 => array:2 [ "nombre" => "Kenneth" "apellidos" => "Kwok" ] 10 => array:2 [ "nombre" => "Ricardo" "apellidos" => "Rojo" ] 11 => array:2 [ "nombre" => "Erika Gabriela" "apellidos" => "García" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574317300849" "doi" => "10.1016/j.reumae.2016.04.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317300849?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X16300407?idApp=UINPBA00004M" "url" => "/1699258X/0000001300000004/v1_201706290122/S1699258X16300407/v1_201706290122/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1699258X16300444" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2016.04.014" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "928" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2017;13:189-96" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3338 "formatos" => array:3 [ "EPUB" => 177 "HTML" => 2286 "PDF" => 875 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Evaluación de la implementación de un programa integrado de atención a las enfermedades del aparato locomotor" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "189" "paginaFinal" => "196" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Evaluation of the implementation of an integrated program for musculoskeletal system care" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figura 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1249 "Ancho" => 3249 "Tamanyo" => 257925 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">A. Análisis de impacto presupuestario 2012-2020 utilizando los costes unitarios referentes al año 2012. B. Integración del coste real en el análisis de impacto presupuestario 2012-2020.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Igor Larrañaga, Myriam Soto-Gordoa, Arantzazu Arrospide, María Luz Jauregi, Jesús Millas, Ricardo San Vicente, Jabier Aguirrebeña, Javier Mar" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Igor" "apellidos" => "Larrañaga" ] 1 => array:2 [ "nombre" => "Myriam" "apellidos" => "Soto-Gordoa" ] 2 => array:2 [ "nombre" => "Arantzazu" "apellidos" => "Arrospide" ] 3 => array:2 [ "nombre" => "María Luz" "apellidos" => "Jauregi" ] 4 => array:2 [ "nombre" => "Jesús" "apellidos" => "Millas" ] 5 => array:2 [ "nombre" => "Ricardo" "apellidos" => "San Vicente" ] 6 => array:2 [ "nombre" => "Jabier" "apellidos" => "Aguirrebeña" ] 7 => array:2 [ "nombre" => "Javier" "apellidos" => "Mar" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574317300618" "doi" => "10.1016/j.reumae.2016.04.013" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317300618?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X16300444?idApp=UINPBA00004M" "url" => "/1699258X/0000001300000004/v1_201706290122/S1699258X16300444/v1_201706290122/es/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Association between serum dickkopf-1 levels and disease duration in axial spondyloarthritis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "197" "paginaFinal" => "200" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Roxana Rubio Vargas, Enrique Melguizo Madrid, Concepción González Rodríguez, Federico Navarro Sarabia, Carmen Dominguez Quesada, Rafael Ariza Ariza, Victoria Navarro Compán" "autores" => array:7 [ 0 => array:4 [ "nombre" => "Roxana" "apellidos" => "Rubio Vargas" "email" => array:1 [ 0 => "roxanarubio27@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Enrique" "apellidos" => "Melguizo Madrid" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Concepción" "apellidos" => "González Rodríguez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Federico" "apellidos" => "Navarro Sarabia" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 4 => array:3 [ "nombre" => "Carmen" "apellidos" => "Dominguez Quesada" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "Rafael" "apellidos" => "Ariza Ariza" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "Victoria" "apellidos" => "Navarro Compán" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Department of Rheumatology, University Hospital Virgen Macarena, Seville, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Biochemistry Department, University Hospital Virgen Macarena, Seville, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Department of Rheumatology, IdiPaz, University Hospital La Paz, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Asociación entre niveles séricos de Dickkopf-1 y duración de la enfermedad en espondiloartritis axial" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that mainly affects the spine and sacroiliac joints. Structural damage in axSpA is characterized by new bone formation leading to syndesmophytes, bone bridges and complete ankylosis. The complex systems that underlie new bone formation in patients with axSpA involve Wingless protein (Wnt) signaling and growth factors such as the bone morphogenetic proteins (BMPs).</p><p id="par0010" class="elsevierStylePara elsevierViewall">An important inhibitor of the Wnt signaling is dickkopf-related protein 1 (DKK-1), which seems to be enhanced by tumor necrosis factor alpha (TNF). Serum DKK-1 levels are decreased in patients with axSpA compared with healthy controls<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a> and other rheumatic inflammatory diseases such as rheumatoid arthritis.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">2</span></a> Additionally, it has been shown that DKK-1 serum levels are related to radiographic progression in patients with axSpA.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">3</span></a> Specifically, high levels of functional DKK-1 seems to be protective of the development of syndesmophytes,<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a> and DKK-1 blockade leads to the fusion of sacroiliac joints in an animal model of arthritis.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">5</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Furthermore, the mechanisms and characteristics influencing serum DKK-1 levels in patients with axSpA are unclear. In principle, the most accepted hypothesis is that TNF induces DKK-1,<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a> which down-regulates bone formation through inhibition of Wnt signaling. However, the change produced in DKK-1 serum levels after treatment with TNF blockers is not yet conclusive since different results (decrease, increase and even no change on DKK-1) have been reported in this sense.<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">7–9</span></a> In addition, TNF blockers have shown clinical efficacy in patients with axSpA,<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">10</span></a> but inhibition or slowing radiographic progression with this therapy has not been demonstrated.<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">11–13</span></a> Based on this, it may be hypothesized that inflammation and radiographic progression are uncoupled processes in axSpA.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Furthermore, all these data come from studies including patients with long-standing and established disease.<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">11–13</span></a> The influence of disease duration on DKK-1 levels is unknown since no study has previously assessed whether or not patients at early stages of the disease have the same decreased levels of DKK-1 than patients with longstanding and established disease. Based on this, the aim of this study is to investigate if disease duration influences on serum levels of DKK-1 in patients with axSpA.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Materials and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Study design, population and data collection</span><p id="par0025" class="elsevierStylePara elsevierViewall">A cross-sectional study in which consecutive patients with axSpA attending the outpatient clinic of a tertiary hospital between January 2011 and June 2014 were included. Patients should fulfill Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA and be naïve for treatment with TNF blockers or other biological therapy.</p><p id="par0030" class="elsevierStylePara elsevierViewall">The following data were collected: demographic characteristics including age and gender; disease characteristics specifying symptoms duration, human leukocyte antigen B27 (HLA-B27) and presence or previous history of SpA features including psoriasis, inflammatory bowel disease, uveitis or peripheral arthritis; and concomitant treatment. Disease Activity was measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Ankylosing Spondylitis Disease Activity Score (ASDAS), patient's visual analog score of disease activity (Patient's VAS) and C-Reactive Protein (CRP). Enthesitis was assessed using the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and function was evaluated through the Bath Ankylosing Spondylitis Functional Index (BASFI). A physical examination was also performed to assess mobility, measured by the Bath Ankylosing Spondylitis Mobility Index (BASMI). Blood samples to determine Dkk-1 serum levels by enzyme immunoassay were collected too. In addition, based on symptoms duration patients were classified in two groups: early axSpA (less than or equal to 5 years) and established axSpA (more than 5 years). This study was approved by the local ethical committee, and all patients signed a written informed consent before being included.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Quantification of dickkopf-1 (Dkk-1) levels</span><p id="par0035" class="elsevierStylePara elsevierViewall">Serum samples were obtained through venous punctures and stored at −80<span class="elsevierStyleHsp" style=""></span>°C until assays were performed. Commercially available kit was used (Biomedica Medizinprodukte GmbH & Co KG, A-1210 Wien, Divischgasse 4). Serum samples were diluted 2:7 and were processed by an enzyme immunoassay. DKK-1 levels were estimated by means of colourimetric measurements at 450<span class="elsevierStyleHsp" style=""></span>nm and by interpolation from a standard curve (0–160<span class="elsevierStyleHsp" style=""></span>pM) on an ELISA plate reader, obtaining DKK-1 serum concentrations in pM. The intra- and inter-assay coefficients of variation were <3%.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Statistical analysis</span><p id="par0040" class="elsevierStylePara elsevierViewall">First, a descriptive analysis was performed. For this purpose, collected variables between patients with early and established axSpA were compared using Student <span class="elsevierStyleItalic">t</span>-test for continuous variables and chi-square test for categorical variables. The results are presented as mean and standard deviation (SD) for continuous variables and as percentage and relative frequencies for categorical variables. Second, separate linear regression models adjusted for age and gender were employed for identifying the variables related to serum levels of DKK-1. For all the analyses, SPSS software version 21.0 was employed and <span class="elsevierStyleItalic">p</span>-values less than 0.05 were considered statistically significant.</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Results</span><p id="par0045" class="elsevierStylePara elsevierViewall">Ninety patients with axSpA were included in this study. Sixty-eight patients were classified as early axSpA and 22 as established disease. Results for demographic, disease characteristics and biomarkers in each group of patients are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. Compared to patients with established disease, patients with early axSpA were younger, had a higher proportion of females, lower degree of disease activity and less enthesis involvement. As expected, they also had higher mobility range aside from a better function.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0050" class="elsevierStylePara elsevierViewall">Importantly, DKK-1 serum levels were found to be statistically significant higher in patients with early axSpA compared with patients with established disease (22.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>12.6 vs 16.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>10.7<span class="elsevierStyleHsp" style=""></span>pM; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.04, respectively).</p><p id="par0055" class="elsevierStylePara elsevierViewall">Furthermore, <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> shows the results for the separate linear regression models evaluating the association between DKK-1 serum levels and symptom duration, disease activity, function and mobility. Among all the tested variables, only symptom duration was statistically significant related to DKK-1 serum levels (standard <span class="elsevierStyleItalic">β</span>: −0.041; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.01). This relationship was inverse: as disease duration increased, DKK-1 serum levels decreased.</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Discussion</span><p id="par0060" class="elsevierStylePara elsevierViewall">This study shows that DKK-1 serum levels in patients with axSpA depend on symptom duration. Independently of the age and gender, patients with early axSpA have higher serum DKK-1 levels compared with patients with established disease.</p><p id="par0065" class="elsevierStylePara elsevierViewall">These findings are consistent with published data, in which low serum levels of DKK-1 in patients with established ankylosing spondylitis have been observed.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">1,14,15</span></a> On the other hand, opposite to a previous study, an association between disease activity and DKK-1 levels was not found.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">15</span></a> In our study, most patients had active or very active disease activity while in the study of Korskos et al. the degree of disease activity was more heterogeneous. This may explain the difference on the results between the studies.</p><p id="par0070" class="elsevierStylePara elsevierViewall">The difference on DKK-1 serum levels found in our study between patients with early and established axSpA may be relevant to understand why despite suppressing inflammation, TNF blockers have not shown to inhibit the development of syndesmophytes in patients with axSpA. On one hand, disease activity has been longitudinally related to radiographic progression in patients with axSpA.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">16</span></a> On the other hand, TNF blockers decrease disease activity but have not shown to inhibit new bone formation in patients with axSpA.<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">11–13</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">In addition, it has been shown that low levels of serum DKK-1 are necessary to develop syndesmophytes.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a> What is unclear is the relationship between TNF and DKK-1. TNF stimulates DKK-1 but previous studies have found that inhibition of TNF by TNF-blockers does not necessarily lead to the decrease of serum DKK-1.<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">7,9</span></a> This highlights the fact that there may be more important factors different than TNF regulating DKK-1 production. As shown in the results of our study, in patients with established axSpA DKK-1 serum levels are already decreased.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">17</span></a> This may explain why despite suppressing disease activity, the administration of a more intensive therapy such as TNF-blockers in a late stage of the disease is not able to avoid the development of syndesmophytes. Nevertheless, this situation may be different in patients at an early stage of the disease, in which DKK-1 serum levels are not decreased yet. Based on this, initiation of TNF-blockers at early stages of the disease in patients with axSpA could have a different (better) outcome on inhibiting or slowing radiographic progression. So, these results support the hypothesis of a window of opportunity to treat patients with axSpA if the avoidance of irreversible radiographic damage is desired.</p><p id="par0080" class="elsevierStylePara elsevierViewall">The following process has been postulated to explain how inflammation could lead to new bone formation in axSpA<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">18</span></a>: First, the initial development of inflammation causes erosive cartilage and bone destruction. Later, these lesions are filled in by fibrous tissue. And finally, this tissue is ossified leading to syndesmophytes. This process is mediated by TNF-alfa and Dkk-1. TNF-blockers target the sites of active inflammation but have no direct effects on osteoproliferation.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">18</span></a> In other words, it could be postulated that TNF-blockers block the transformation from inflammation to erosion; however, they don’t block the transformation from erosion to osteoproliferation, where non-steroidal anti-inflammatory drugs might have a role.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">19</span></a> This may explain why initiation of TNF-blockers at early stages of the disease could have a better outcome on the development of radiographic progression.</p><p id="par0085" class="elsevierStylePara elsevierViewall">Furthermore, several limitations of this study should be taken into account when interpreting its results. First, this is a cross-sectional study, which does not allow investigating if DKK-1 serum levels truly decrease overtime. Second, no control group was included so it is not possible to know whether patients with early axSpA have similar or lower serum levels of DKK-1 than healthy population. Third, the group of patients with established disease was substantially smaller than the group with early disease and a bigger sample size in this group could have an impact. Finally, no radiographs were available to assess radiographic damage or progression in these patients.</p><p id="par0090" class="elsevierStylePara elsevierViewall">In summary, DKK-1 serum levels depend on symptom duration in patients with axSpA. Patients with early disease have higher serum DKK-1 levels compared with patients with established axSpA. Based on the results of the current study, it can be concluded that serum DKK-1 levels are not decreased from the beginning of the disease in patients with axSpA but they decrease as disease duration increases. This could underlie a window of opportunity to avoid development of new bone formation through TNF-blockers in patients with axSpA. Nevertheless, further data from longitudinal studies are necessary to confirm this.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Ethical responsibilities</span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Protection of people and animals</span><p id="par0095" class="elsevierStylePara elsevierViewall">The authors state that the procedures conformed to the ethical standards of human experimentation committee responsible and according to the World Medical Association and the Declaration of Helsinki.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Confidentiality of data</span><p id="par0100" class="elsevierStylePara elsevierViewall">The authors declare that they have followed the protocols of the workplace on the publication of patient data.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Right to privacy and informed consent</span><p id="par0105" class="elsevierStylePara elsevierViewall">The authors declare that this article does not appear patient data.</p></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Funding</span><p id="par0110" class="elsevierStylePara elsevierViewall">This work was supported by an Initiated Investigator Research (<span class="elsevierStyleGrantSponsor" id="gs1">IIR</span>) grant from Pfizer, the <span class="elsevierStyleGrantSponsor" id="gs2">Institute Carlos III</span> (PI10/01963) and the <span class="elsevierStyleGrantSponsor" id="gs3">Spanish Society of Rheumatology</span> (call 2010).</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Conflicts of interest</span><p id="par0115" class="elsevierStylePara elsevierViewall">All authors declare no conflicts of interest in this manuscript.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:3 [ "identificador" => "xres857908" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Material and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusion" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec852042" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres857909" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Material y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec852041" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Materials and methods" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Study design, population and data collection" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Quantification of dickkopf-1 (Dkk-1) levels" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Statistical analysis" ] ] ] 6 => array:2 [ "identificador" => "sec0030" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0035" "titulo" => "Discussion" ] 8 => array:3 [ "identificador" => "sec0040" "titulo" => "Ethical responsibilities" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0045" "titulo" => "Protection of people and animals" ] 1 => array:2 [ "identificador" => "sec0050" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0055" "titulo" => "Right to privacy and informed consent" ] ] ] 9 => array:2 [ "identificador" => "sec0060" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "sec0065" "titulo" => "Conflicts of interest" ] 11 => array:2 [ "identificador" => "xack287593" "titulo" => "Acknowledgments" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-01-26" "fechaAceptado" => "2016-04-29" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec852042" "palabras" => array:3 [ 0 => "DKK-1" 1 => "Disease duration" 2 => "Axial spondyloarthritis" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec852041" "palabras" => array:3 [ 0 => "DKK-1" 1 => "Duración de la enfermedad" 2 => "Espondiloartritis axial" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Axial spondyloarthritis (axSpA) is characterized by new bone formation. The complex systems underlying this process involve Wnt-signaling pathway. It has been observed that serum levels of dickkopf-1 (DKK-1), an important inhibitor of Wnt-signaling, are decreased in patients with axSpA. However, these data are from studies including only patients with long-standing disease.</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">The aim of this study is to investigate if symptom duration influences on serum DKK-1 levels in patients with axSpA.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Material and methods</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">A cross-sectional study including consecutive patients with axSpA (ASAS criteria) naïve for anti-TNF therapy. Collected data included demographic and disease characteristics, time since first symptom onset, assessment of disease activity and function, and determination of DKK-1 serum levels. Patients were classified as early axSpA (symptom duration ≤5 years) and established axSpA (>5 years). Linear regression models were employed to investigate the variables related to DKK-1 serum levels.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">In total, 90 patients were included. Sixty-eight patients had early axSpA and 22 had established disease. Serum levels of DKK-1 were significantly higher in patients with early axSpA compared with established axSpA (22.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>12.6 vs 16.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>10.7<span class="elsevierStyleHsp" style=""></span>pM; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.04). Among all tested variables, only symptom duration was significantly and inversely correlated with DKK-1 serum levels (beta: −0.041; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.01).</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusion</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Serum DKK-1 levels in axSpA depend on disease duration. As disease duration increases, DKK-1 serum levels decrease. Based on this, an intensive treatment at early stages of the disease could have a better outcome on inhibiting/slowing radiographic progression in patients with axSpA.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Material and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusion" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Espondiloartritis axial (EsPax) se caracteriza por nueva formación ósea. El complejo sistema que subyace este proceso incluye la vía de señal Wnt. Se ha demostrado que niveles séricos de dickkopf-1 (DKK-1), un importante inhibidor de la vía de señal Wnt, está disminuidos en pacientes con EsPax. Sin embargo, estos datos proceden exclusivamente de pacientes con EsPax de larga duración.</p><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">El objetivo de este estudio es investigar si la duración de la enfermedad influye en niveles séricos de DKK-1 en pacientes con EsPax.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Material y métodos</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Estudio transversal en pacientes con EsPax sin terapia anti-TNF. Se recogieron datos demográficos y de la enfermedad, y se determinaron niveles de DKK-1 séricos en la misma visita. Los pacientes fueron clasificados en base a la duración de síntomas en EsPax precoz (≤5 años) y establecida (>5 años). Se emplearon modelos de regresión lineal para investigar las variables asociadas con los niveles de DKK-1.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Se incluyeron 90 pacientes, 68 con EsPax precoz y 22 con EsPax establecida. Los niveles de DKK-1 fueron superiores en EsPax precoz comparado con EsPax establecida (22.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>12.6 vs 16.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>10.7<span class="elsevierStyleHsp" style=""></span>pM; p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.04). De todas las variables, sólo la duración de síntomas se asoció significativamente con DKK-1 (beta: −0.041; p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.01).</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Los niveles séricos de DKK-1 en EsPax, dependen de la duración de la enfermedad. A medida que la duración de la enfermedad aumenta, niveles séricos de DKK-1 disminuye. Por lo tanto, el tratamiento intensivo en estadios tempranos de la enfermedad podría tener un mejor resultado en inhibir/disminuir la progresión radiológica en pacientes con EsPax.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Material y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; CRP: C Reactive Protein; Patient's VAS: patient's global visual analog scale; BASFI: Bath Ankylosing Spondylitis Functional Index; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; BASMI: Bath Ankylosing Spondylitis Metrology Index; NSAID: Nonsteroidal Anti-Inflammatory Drugs; DKK-1: Dickkopf-1. Results are shown as mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>standard deviation or absolute number with percentages. <span class="elsevierStyleItalic">p</span> value in bold: with statistical significance.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Early axSpA<br><span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>68 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Established axSpA<br><span class="elsevierStyleItalic">N</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>22 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> value \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Age (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">34.6<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>9.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">43.2<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.01</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Gender (male, %) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">48 (70.6%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">20 (90.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.05</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Symptoms duration (months) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">19.3<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>17.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">183.3<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>112.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.001</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Uveitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3 (4.4%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 (31.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.01</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Peripheral arthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">38 (55.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14 (63.6%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 (5.9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 (18.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.09 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Inflammatory bowel disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9 (14.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 (4.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">HLA-B27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">44 (68.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17 (85%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BASDAI (0–10) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5.3<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold">0.001</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">ASDAS-CRP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.9<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.8<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>0.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.001</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CRP (mg/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10.5<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>17.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17.8<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>21.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patient's VAS (0–100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">50.5<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>27.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">70.0<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>22.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.01</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BASFI (0–10) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.5<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.001</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">MASES (0–13) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.5<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>2.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.01</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BASMI (0–10) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.7<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>1.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.001</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Concomitant NSAID \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">40 (58.8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15 (68.2%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.01</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">DKK-1 (pM) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">22.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>12.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16.4<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>10.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold">0.04</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1449262.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Demographic, disease characteristics and biomarkers based on symptoms duration.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; CRP: C Reactive Protein; Patient's VAS: patient's global visual analog scale of disease activity; BASFI: Bath Ankylosing Spondylitis Functional Index; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; BASMI: Bath Ankylosing Spondylitis Metrology Index; Beta: unstandardized beta coefficient; Std. error: standard error. All models are adjusted for age and gender. <span class="elsevierStyleItalic">p</span> value in bold: with statistical significance.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Beta \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Std. error \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> value \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Symptom duration (months) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.041 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.016 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><span class="elsevierStyleBold"><0.01</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">HLA-B27 positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−2.626 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.129 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−1.281 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4.671 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Inflammatory bowel disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−3.214 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4.386 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Uveitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.454 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4.253 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Peripheral arthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.809 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.687 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BASDAI (0–10) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.285 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.589 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">ASDAS (CRP) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.034 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.231 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CRP (mg/L) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.055 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.074 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Patient's VAS (0–100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">−0.014 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.050 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BASFI (0–10) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.075 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.479 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.9 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">MASES (0–13) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.499 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.8 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">BASMI (0–10) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.478 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.041 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.6 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1449261.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Separate linear regression models for the association between DKK-1 and disease characteristics.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:19 [ 0 => array:3 [ "identificador" => "bib0100" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.-R. Kwon" 1 => "M.-J. Lim" 2 => "C.-H. Suh" 3 => "S.-G. Park" 4 => "Y.-S. Hong" 5 => "B.-Y. Yoon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-011-1981-0" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "2012" "volumen" => "32" "paginaInicial" => "2523" "paginaFinal" => "2527" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21833531" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0105" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.-Y. Wang" 1 => "Y.-Y. Liu" 2 => "H. Ye" 3 => "J.-P. Guo" 4 => "R. Li" 5 => "X. Liu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3899/jrheum.100089" "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2011" "volumen" => "38" "paginaInicial" => "821" "paginaFinal" => "827" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21362762" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0110" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Z. Yucong" 1 => "L. Lu" 2 => "L. Shengfa" 3 => "Y. Yongliang" 4 => "S. Ruguo" 5 => "L. Yikai" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Lab" "fecha" => "2014" "volumen" => "60" "paginaInicial" => "1527" "paginaFinal" => "1531" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25291949" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0115" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.R. Heiland" 1 => "H. Appel" 2 => "D. Poddubnyy" 3 => "J. Zwerina" 4 => "A. Hueber" 5 => "H. Haibel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2011-200216" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2012" "volumen" => "71" "paginaInicial" => "572" "paginaFinal" => "574" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22186710" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0120" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Uderhardt" 1 => "D. Diarra" 2 => "J. Katzenbeisser" 3 => "J.-P. David" 4 => "J. Zwerina" 5 => "W. Richards" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2008.102046" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2010" "volumen" => "69" "paginaInicial" => "592" "paginaFinal" => "597" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19304568" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0125" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New bone formation in axial spondyloarthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D. Wendling" 1 => "P. Claudepierre" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Jt Bone Spine Rev Rhum" "fecha" => "2013" "volumen" => "80" "paginaInicial" => "454" "paginaFinal" => "458" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0130" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Daoussis" 1 => "Liossis S-NC" 2 => "E.E. Solomou" 3 => "A. Tsanaktsi" 4 => "K. Bounia" 5 => "M. Karampetsou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.27231" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2010" "volumen" => "62" "paginaInicial" => "150" "paginaFinal" => "158" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20039407" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0135" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Korkosz" 1 => "J. Gąsowski" 2 => "P. Leszczyński" 3 => "K. Pawlak-Buś" 4 => "S. Jeka" 5 => "M. Siedlar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/03009742.2013.805241" "Revista" => array:6 [ "tituloSerie" => "Scand J Rheumatol" "fecha" => "2014" "volumen" => "43" "paginaInicial" => "43" "paginaFinal" => "48" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24447112" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0140" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Taylan" 1 => "I. Sari" 2 => "B. Akinci" 3 => "S. Bilge" 4 => "D. Kozaci" 5 => "S. Akar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2474-13-191" "Revista" => array:5 [ "tituloSerie" => "BMC Musculoskelet Disord" "fecha" => "2012" "volumen" => "13" "paginaInicial" => "191" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23025387" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0145" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Callhoff" 1 => "J. Sieper" 2 => "A. Weiß" 3 => "A. Zink" 4 => "J. Listing" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2014-205322" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2015" "volumen" => "74" "paginaInicial" => "1241" "paginaFinal" => "1248" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24718959" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0150" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. van der Heijde" 1 => "R. Landewé" 2 => "X. Baraliakos" 3 => "H. Houben" 4 => "A. van Tubergen" 5 => "P. Williamson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23901" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "3063" "paginaFinal" => "3070" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18821688" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0155" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. van der Heijde" 1 => "R. Landewé" 2 => "S. Einstein" 3 => "P. Ory" 4 => "D. Vosse" 5 => "L. Ni" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23471" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "1324" "paginaFinal" => "1331" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18438853" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0160" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. van der Heijde" 1 => "D. Salonen" 2 => "B.N. Weissman" 3 => "R. Landewé" 4 => "W.P. Maksymowych" 5 => "H. Kupper" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/ar2794" "Revista" => array:5 [ "tituloSerie" => "Arthritis Res Ther" "fecha" => "2009" "volumen" => "11" "paginaInicial" => "R127" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19703304" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0165" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dickkopf-1 is a master regulator of joint remodeling" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Diarra" 1 => "M. Stolina" 2 => "K. Polzer" 3 => "J. Zwerina" 4 => "M.S. Ominsky" 5 => "D. Dwyer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nm1538" "Revista" => array:6 [ "tituloSerie" => "Nat Med" "fecha" => "2007" "volumen" => "13" "paginaInicial" => "156" "paginaFinal" => "163" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17237793" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0170" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Korkosz" 1 => "J. Gąsowski" 2 => "P. Leszczyński" 3 => "K. Pawlak-Buś" 4 => "S. Jeka" 5 => "E. Kucharska" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2474-14-99" "Revista" => array:5 [ "tituloSerie" => "BMC Musculoskelet Disord" "fecha" => "2013" "volumen" => "14" "paginaInicial" => "99" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23509994" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0175" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Ramiro" 1 => "D. van der Heijde" 2 => "A. van Tubergen" 3 => "C. Stolwijk" 4 => "M. Dougados" 5 => "F. van den Bosch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2014-205178" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2014" "volumen" => "73" "paginaInicial" => "1455" "paginaFinal" => "1461" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24812292" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0180" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sclerostin and Dkk-1 in patients with ankylosing spondylitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Ustun" 1 => "F. Tok" 2 => "U. Kalyoncu" 3 => "S. Motor" 4 => "R. Yuksel" 5 => "A.E. Yagiz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Reumatol Port" "fecha" => "2014" "volumen" => "39" "paginaInicial" => "146" "paginaFinal" => "151" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25111416" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0185" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J. Sieper" 1 => "H. Appel" 2 => "J. Braun" 3 => "M. Rudwaleit" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23260" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "649" "paginaFinal" => "656" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18311819" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0190" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Wanders" 1 => "D. Heijde" 2 => "van der" 3 => "R. Landewé" 4 => "J.-M. Béhier" 5 => "A. Calin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21054" "Revista" => array:7 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2005" "volumen" => "52" "paginaInicial" => "1756" "paginaFinal" => "1765" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15934081" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1808869415303232" "estado" => "S300" "issn" => "18088694" ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack287593" "titulo" => "Acknowledgments" "texto" => "<p id="par0120" class="elsevierStylePara elsevierViewall">We are grateful to all the patients that participated in this study for their collaboration. In addition, we would like to thank Cristian Leyva, Rufino Mondéjar, Virginia Moreira and Consuelo Leon, who participated in the determination and collection of clinical and laboratory variables. We also thank Ismael Gómez for medical advisory support.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/1699258X/0000001300000004/v1_201706290122/S1699258X16300432/v1_201706290122/en/main.assets" "Apartado" => array:4 [ "identificador" => "17499" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Originales" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/1699258X/0000001300000004/v1_201706290122/S1699258X16300432/v1_201706290122/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X16300432?idApp=UINPBA00004M" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 4 | 12 | 16 |
2024 Octubre | 37 | 38 | 75 |
2024 Septiembre | 29 | 14 | 43 |
2024 Agosto | 53 | 33 | 86 |
2024 Julio | 35 | 31 | 66 |
2024 Junio | 29 | 17 | 46 |
2024 Mayo | 41 | 23 | 64 |
2024 Abril | 38 | 20 | 58 |
2024 Marzo | 43 | 40 | 83 |
2024 Febrero | 31 | 29 | 60 |
2024 Enero | 29 | 27 | 56 |
2023 Diciembre | 26 | 23 | 49 |
2023 Noviembre | 28 | 23 | 51 |
2023 Octubre | 36 | 34 | 70 |
2023 Septiembre | 66 | 35 | 101 |
2023 Agosto | 31 | 14 | 45 |
2023 Julio | 31 | 30 | 61 |
2023 Junio | 26 | 18 | 44 |
2023 Mayo | 34 | 26 | 60 |
2023 Abril | 24 | 11 | 35 |
2023 Marzo | 40 | 31 | 71 |
2023 Febrero | 38 | 27 | 65 |
2023 Enero | 28 | 13 | 41 |
2022 Diciembre | 59 | 46 | 105 |
2022 Noviembre | 61 | 28 | 89 |
2022 Octubre | 56 | 25 | 81 |
2022 Septiembre | 53 | 39 | 92 |
2022 Agosto | 84 | 39 | 123 |
2022 Julio | 83 | 36 | 119 |
2022 Junio | 32 | 41 | 73 |
2022 Mayo | 57 | 47 | 104 |
2022 Abril | 32 | 55 | 87 |
2022 Marzo | 38 | 68 | 106 |
2022 Febrero | 40 | 44 | 84 |
2022 Enero | 39 | 39 | 78 |
2021 Diciembre | 42 | 47 | 89 |
2021 Noviembre | 31 | 48 | 79 |
2021 Octubre | 65 | 68 | 133 |
2021 Septiembre | 36 | 37 | 73 |
2021 Agosto | 28 | 45 | 73 |
2021 Julio | 26 | 20 | 46 |
2021 Junio | 33 | 28 | 61 |
2021 Mayo | 59 | 50 | 109 |
2021 Abril | 107 | 73 | 180 |
2021 Marzo | 68 | 40 | 108 |
2021 Febrero | 46 | 33 | 79 |
2021 Enero | 41 | 29 | 70 |
2020 Diciembre | 47 | 31 | 78 |
2020 Noviembre | 43 | 12 | 55 |
2020 Octubre | 36 | 16 | 52 |
2020 Septiembre | 65 | 34 | 99 |
2020 Agosto | 52 | 32 | 84 |
2020 Julio | 29 | 14 | 43 |
2020 Junio | 37 | 11 | 48 |
2020 Mayo | 34 | 25 | 59 |
2020 Abril | 25 | 21 | 46 |
2020 Marzo | 46 | 32 | 78 |
2020 Febrero | 38 | 25 | 63 |
2020 Enero | 40 | 22 | 62 |
2019 Diciembre | 36 | 26 | 62 |
2019 Noviembre | 30 | 23 | 53 |
2019 Octubre | 24 | 17 | 41 |
2019 Septiembre | 29 | 36 | 65 |
2019 Agosto | 27 | 15 | 42 |
2019 Julio | 35 | 25 | 60 |
2019 Junio | 29 | 22 | 51 |
2019 Mayo | 37 | 55 | 92 |
2019 Abril | 29 | 22 | 51 |
2019 Marzo | 31 | 33 | 64 |
2019 Febrero | 29 | 18 | 47 |
2019 Enero | 56 | 22 | 78 |
2018 Diciembre | 112 | 45 | 157 |
2018 Noviembre | 123 | 16 | 139 |
2018 Octubre | 74 | 11 | 85 |
2018 Septiembre | 35 | 13 | 48 |
2018 Agosto | 29 | 12 | 41 |
2018 Julio | 10 | 6 | 16 |
2018 Mayo | 2 | 1 | 3 |
2018 Abril | 89 | 11 | 100 |
2018 Marzo | 50 | 11 | 61 |
2018 Febrero | 43 | 6 | 49 |
2018 Enero | 24 | 9 | 33 |
2017 Diciembre | 31 | 13 | 44 |
2017 Noviembre | 35 | 11 | 46 |
2017 Octubre | 26 | 12 | 38 |
2017 Septiembre | 49 | 12 | 61 |
2017 Agosto | 97 | 32 | 129 |
2017 Julio | 200 | 51 | 251 |
2017 Junio | 24 | 26 | 50 |
2017 Mayo | 0 | 18 | 18 |
2017 Abril | 0 | 8 | 8 |
2017 Marzo | 0 | 10 | 10 |
2017 Febrero | 0 | 10 | 10 |
2017 Enero | 0 | 13 | 13 |
2016 Diciembre | 0 | 31 | 31 |
2016 Noviembre | 0 | 25 | 25 |
2016 Octubre | 0 | 29 | 29 |
2016 Septiembre | 7 | 10 | 17 |
2016 Agosto | 26 | 11 | 37 |
2016 Julio | 8 | 5 | 13 |